GRAIL Inc. (GRAL)

2 Growth Stocks to Buy in October

Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?

GRAIL (NASDAQ:GRAL) Shares Climb 5.5% – Time to Buy?

GRAIL (NASDAQ:GRAL) Hits New 12-Month High – Should You Buy?

3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.

Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in Stock

Here's Why Grail Stock Surged 55% This Week

GRAIL (NASDAQ:GRAL) CEO Joshua Ofman Sells 61,452 Shares

Owning a Home Is Seen as a Financial Holy Grail. But What If It Isn't?

Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval

FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test

FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy

GRAIL: Stock Surges As Market Digests FDA Briefing Docs - I Broadly Concur (Rating Upgrade)

Low False Positives and High Accuracy: FDA Document Fueling Grail Stock Surge

Grail rallies as FDA staff flags no major concerns for multi-cancer test

Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review From FDA

GRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript